Skip to main content

Articles

Page 1 of 59

  1. The clinical use of calcitonin gene-related peptide receptor (CGRP-R) antagonists and monoclonal antibodies against CGRP and CGRP-R has offered new treatment possibilities for migraine patients. CGRP activates...

    Authors: Sanne Hage La Cour, Kiki Juhler, Lisette J. A. Kogelman, Jes Olesen, Dan Arne Klærke, David Møbjerg Kristensen and Inger Jansen-Olesen
    Citation: The Journal of Headache and Pain 2022 23:59
  2. Cluster headache is a less-prevalent primary headache disorder but is overrepresented with regards to use of health care and social services. More insight into the socioeconomic impact is required.

    Authors: Anja Sofie Petersen, Nunu Lund, Agneta Snoer, Rigmor Højland Jensen and Mads Barloese
    Citation: The Journal of Headache and Pain 2022 23:58
  3. Authors: Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen, Xiaoping Ning, Lindsay Janka, Verena Ramirez Campos, Lynda J. Krasenbaum, Dagny Holle-Lee, David Kudrow and Christian Lampl
    Citation: The Journal of Headache and Pain 2022 23:57

    The original article was published in The Journal of Headache and Pain 2021 22:141

  4. Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults. The efficacy a...

    Authors: Maurice T. Driessen, Joshua M. Cohen, Stephen F. Thompson, Oscar Patterson-Lomba, Michael J. Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu and Rajeev Ayyagari
    Citation: The Journal of Headache and Pain 2022 23:56
  5. Erenumab is a monoclonal antibody (mAb) against the calcitonin gene related peptide (CGRP) receptor and is commonly used in migraine prophylaxis. Pivotal and open-label studies show a good safety and tolerabil...

    Authors: Hannah Schenk, Dagny Holle, Michael Nsaka, Christoph Kleinschnitz, Martin Glas and Armin Scheffler
    Citation: The Journal of Headache and Pain 2022 23:55
  6. Following approval of fremanezumab for the prevention of migraine in adults, health care decision makers are interested in understanding real-world clinical characteristics and treatment patterns among patient...

    Authors: Lynda J. Krasenbaum, Vasantha L. Pedarla, Stephen F. Thompson, Krishna Tangirala, Joshua M. Cohen and Maurice T. Driessen
    Citation: The Journal of Headache and Pain 2022 23:54
  7. Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide (CGRP) pathway raised new hopes. CGRP, a potent vasodilator, plays a key ro...

    Authors: Alexandre O. Gérard, Diane Merino, Elise K. Van Obberghen, Fanny Rocher, Alexandre Destere, Michel Lantéri-Minet and Milou-Daniel Drici
    Citation: The Journal of Headache and Pain 2022 23:53
  8. The discovery of the prominent action of Calcitonin Gene Related Peptide –CGRP- on trigeminal afferents and meningeal vessels, opened a new era in migraine treatment. However, how the block of nociceptive affe...

    Authors: Marina de Tommaso, Marianna La Rocca, Silvia Giovanna Quitadamo, Katia Ricci, Giusy Tancredi, Livio Clemente, Eleonora Gentile, Elena Ammendola and Marianna Delussi
    Citation: The Journal of Headache and Pain 2022 23:52
  9. Authors: Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi and Fabrizio Vernieri
    Citation: The Journal of Headache and Pain 2022 23:51

    The original article was published in The Journal of Headache and Pain 2022 23:46

  10. Triptans are the first-line option for the acute treatment of migraine attacks; however, triptans are contraindicated in people with certain underlying cardiovascular risk factors and are associated with inade...

    Authors: Richard B. Lipton, Rashmi B. Halker Singh, Dennis A. Revicki, Sihui Zhao, Anand R. Shewale, Jordan E. Lateiner and David W. Dodick
    Citation: The Journal of Headache and Pain 2022 23:50
  11. The Global Campaign against Headache, as a collaborative activity with the World Health Organization (WHO), was formally launched in Copenhagen in March 2004. In the month it turns 18, we review its activities...

    Authors: Timothy J. Steiner, Gretchen L. Birbeck, Rigmor H. Jensen, Paolo Martelletti, Lars Jacob Stovner, Derya Uluduz, Matilde Leonardi, Jes Olesen and Zaza Katsarava
    Citation: The Journal of Headache and Pain 2022 23:49
  12. Eptinezumab 100 mg and 300 mg met the primary efficacy endpoint in both PROMISE clinical trials, significantly reducing frequency of monthly migraine days over Weeks 1‒12. The objective of this analysis was to...

    Authors: Rami Apelian, Lee Boyle, Joe Hirman and Divya Asher
    Citation: The Journal of Headache and Pain 2022 23:48
  13. According to the Global Burden of Disease (GBD) study, headache disorders are among the most prevalent and disabling conditions worldwide. GBD builds on epidemiological studies (published and unpublished) whic...

    Authors: Lars Jacob Stovner, Knut Hagen, Mattias Linde and Timothy J. Steiner
    Citation: The Journal of Headache and Pain 2022 23:34
  14. The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of mig...

    Authors: Maurice T. Driessen, Joshua M. Cohen, Oscar Patterson-Lomba, Stephen F. Thompson, Michael Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu and Rajeev Ayyagari
    Citation: The Journal of Headache and Pain 2022 23:47
  15. Fremanezumab has demonstrated to be effective, safe, and tolerated in the prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials (RCTs). Real-life studies are needed to explor...

    Authors: Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi and Fabrizio Vernieri
    Citation: The Journal of Headache and Pain 2022 23:46

    The Correction to this article has been published in The Journal of Headache and Pain 2022 23:51

  16. Resting-state EEG microstates are thought to reflect brief activations of several interacting components of resting-state brain networks. Surprisingly, we still know little about the role of these microstates ...

    Authors: Yansong Li, Guoliang Chen, Jing Lv, Lei Hou, Zhao Dong, Rongfei Wang, Min Su and Shengyuan Yu
    Citation: The Journal of Headache and Pain 2022 23:45
  17. Anomalous phantom visual perceptions coupled to an aversion and discomfort to some visual patterns (especially grating in mid-range spatial frequency) have been associated with the hyperresponsiveness in migra...

    Authors: Chun Yuen Fong, Wai Him Crystal Law, Johannes Jacobus Fahrenfort, Jason J. Braithwaite and Ali Mazaheri
    Citation: The Journal of Headache and Pain 2022 23:44
  18. Adenosine is a purinergic signaling molecule with a wide range of physiological functions including anti- and pronociceptive properties. Adenosine receptors are expressed in the trigeminovascular system, and a...

    Authors: Janu Thuraiaiyah, Lili Kokoti, Mohammad Al-Mahdi Al-Karagholi and Messoud Ashina
    Citation: The Journal of Headache and Pain 2022 23:43
  19. The incidence of migraines is higher among individuals with epilepsy than in healthy individuals, and these two diseases are thought to shared pathophysiological mechanisms. Excitation/inhibition imbalance pla...

    Authors: Yanjie Zhou, Lily Zhang, Yuyan Hao, Liu Yang, Shanghua Fan and Zheman Xiao
    Citation: The Journal of Headache and Pain 2022 23:42
  20. Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are used to reduce the risk of developing Coronavirus Disease 2019 (COVID-19). Despite the significant benefits in terms of reduced...

    Authors: Matteo Castaldo, Marta Waliszewska-Prosół, Maria Koutsokera, Micaela Robotti, Marcin Straburzyński, Loukia Apostolakopoulou, Mariarita Capizzi, Oneda Çibuku, Fidel Dominique Festin Ambat, Ilaria Frattale, Zukhra Gadzhieva, Erica Gallo, Anna Gryglas-Dworak, Gleni Halili, Asel Jusupova, Yana Koperskaya…
    Citation: The Journal of Headache and Pain 2022 23:41
  21. Migraine frequency increases after the cessation of successful preventive treatment with CGRP(-receptor) monoclonal antibodies (mAbs). In this study, we aimed to evaluate the course of migraine after treatment...

    Authors: Bianca Raffaelli, Maria Terhart, Jasper Mecklenburg, Lars Neeb, Lucas Hendrik Overeem, Anke Siebert, Maureen Steinicke and Uwe Reuter
    Citation: The Journal of Headache and Pain 2022 23:40
  22. Restless legs syndrome is a highly prevalent comorbidity of migraine; however, its genetic contributions remain unclear.

    Authors: Yun-Jin Jiang, Cathy Shen-Jang Fann, Jong-Ling Fuh, Ming-Yi Chung, Hui-Ying Huang, Kuo-Chang Chu, Yen-Feng Wang, Chia-Lin Hsu, Lung-Sen Kao, Shih-Pin Chen and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2022 23:39
  23. Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments have led to reconsidering the outcomes of migraine preven...

    Authors: Raffaele Ornello, Carlo Baraldi, Simona Guerzoni, Giorgio Lambru, Anna P. Andreou, Bianca Raffaelli, Astrid Gendolla, Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Sabina Cevoli, Valentina Favoni, Fabrizio Vernieri, Claudia Altamura, Antonio Russo, Marcello Silvestro…
    Citation: The Journal of Headache and Pain 2022 23:38
  24. Cluster headache (CH) is a severe, highly disabling primary headache disorder. However, there is little research on CH-related disability, and most of it is based on non CH-specific questionnaires. The aim of ...

    Authors: Katharina Kamm, Andreas Straube and Ruth Ruscheweyh
    Citation: The Journal of Headache and Pain 2022 23:37
  25. Certain constituents in migraine food triggers and non-steroidal anti-inflammatory drugs (NSAIDs) inhibit sulfotransferases (SULTs) that detoxify drugs/chemicals and play role in the metabolism of neurotransmi...

    Authors: Doga Vuralli, Burak Arslan, Elif Topa, Andreia Lopes de Morais, Ozlem Gulbahar, Cenk Ayata and Hayrunnisa Bolay
    Citation: The Journal of Headache and Pain 2022 23:36
  26. Vestibular symptoms are frequently reported in patients with chronic migraine (CM). However, whether vestibular symptoms arise through overlapping neurobiology of migraine remains to be elucidated. The neurope...

    Authors: Ruimin Tian, Yun Zhang, Qi Pan, Yunfeng Wang, Qianwen Wen, Xiaoping Fan, Guangcheng Qin, Dunke Zhang, Lixue Chen, Yixin Zhang and Jiying Zhou
    Citation: The Journal of Headache and Pain 2022 23:35
  27. The paper from Steiner et al. suggests that an outcome measure expressed in time units may be an adequate method to assess the impact of headache disorders, regardless of diagnosis or health care setting, prov...

    Authors: Raquel Gil-Gouveia
    Citation: The Journal of Headache and Pain 2022 23:31
  28. Based on the current understanding of the role of neuropeptide signalling in migraine, we explored the therapeutic potential of a specific cannabinoid agonist. The aim of the present study was to examine the e...

    Authors: Isabella Mai Christiansen, Jacob C. A. Edvinsson, Philip V. Reducha, Lars Edvinsson and Kristian Agmund Haanes
    Citation: The Journal of Headache and Pain 2022 23:30
  29. A clinical ability to describe the response trajectory of patients receiving preventive migraine treatment could expedite and improve therapeutic management decisions. This post hoc analysis of the PROMISE-2 s...

    Authors: Dawn C. Buse, Paul K. Winner, Larry Charleston IV, Joe Hirman, Roger Cady and Thomas Brevig
    Citation: The Journal of Headache and Pain 2022 23:29
  30. Current pharmacologic prophylactic strategies for migraine have exhibited limited efficacy, with response rates as low as 40%–50%. In addition to the limited efficacy, the acceptability of those pharmacologic ...

    Authors: Yu-Chen Cheng, Bing-Yan Zeng, Chao-Ming Hung, Kuan-Pin Su, Yi-Cheng Wu, Yu-Kang Tu, Pao-Yen Lin, Brendon Stubbs, Andre F. Carvalho, Chih-Sung Liang, Tien-Yu Chen, Chih-Wei Hsu, Andre R. Brunoni, Mein-Woei Suen, Yow-Ling Shiue, Ping-Tao Tseng…
    Citation: The Journal of Headache and Pain 2022 23:28
  31. Post-traumatic headache (PTH) is a common symptom following mild traumatic brain injury (mTBI). Patients at risk to develop acute PTH (aPTH) and further persistent PTH (pPTH) need to be recognized.

    Authors: Yvonn Kraemer, Kaisa Mäki, Ivan Marinkovic, Taina Nybo, Harri Isokuortti, Antti Huovinen, Antti Korvenoja, Susanna Melkas and Hanna Harno
    Citation: The Journal of Headache and Pain 2022 23:27
  32. 5-Hydroxytryptamine (5-HT) receptors 1B, 1D and 1F have key roles in migraine pharmacotherapy. Selective agonists targeting these receptors, such as triptans and ditans, are effective in aborting acute migrain...

    Authors: Jacob C. A. Edvinsson, Aida Maddahi, Isabella M. Christiansen, Philip V. Reducha, Karin Warfvinge, Majid Sheykhzade, Lars Edvinsson and Kristian A. Haanes
    Citation: The Journal of Headache and Pain 2022 23:26
  33. Central sensitization is an important pathophysiological mechanism of chronic migraine (CM), and microglia activation in trigeminocervical complex (TCC) contributes to the development of central sensitization....

    Authors: Qi Pan, Yunfeng Wang, Ruimin Tian, Qianwen Wen, Guangcheng Qin, Dunke Zhang, Lixue Chen, Yixin Zhang and Jiying Zhou
    Citation: The Journal of Headache and Pain 2022 23:25
  34. Early onset of action has become recognized as an important efficacy feature of preventive migraine treatment, which can help overcome adherence issues commonly associated with older medications. Preventive tr...

    Authors: Takao Takeshima, Masami Nakai, Yoshiyuki Shibasaki, Miki Ishida, Byung-Kun Kim, Xiaoping Ning and Nobuyuki Koga
    Citation: The Journal of Headache and Pain 2022 23:24
  35. PROMISE-1 and PROMISE-2 evaluated the preventive efficacy, tolerability, and safety of eptinezumab, a calcitonin gene-related peptide–targeted monoclonal antibody, in adults with episodic (EM) and chronic migr...

    Authors: Richard B. Lipton, Larry Charleston IV, Cristina Tassorelli, Thomas Brevig, Joe Hirman and Roger Cady
    Citation: The Journal of Headache and Pain 2022 23:23
  36. Demonstrating therapeutic value from the patient perspective is important in patient-centered migraine management. The objective of this study was to investigate the impact of eptinezumab, a preventive migrain...

    Authors: Peter McAllister, Paul K. Winner, Jessica Ailani, Dawn C. Buse, Richard B. Lipton, George Chakhava, Mette Krog Josiassen, Annika Lindsten, Lahar Mehta, Anders Ettrup and Roger Cady
    Citation: The Journal of Headache and Pain 2022 23:22
  37. Migraine has complex pathophysiological characteristics and episodic attacks. To decipher the cyclic neurophysiological features of migraine attacks, in this study, we compared neuronal excitability in the bra...

    Authors: Fu-Jung Hsiao, Wei-Ta Chen, Li-Ling Hope Pan, Hung-Yu Liu, Yen-Feng Wang, Shih-Pin Chen, Kuan-Lin Lai, Gianluca Coppola and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2022 23:21
  38. Angiography headache (AH) is common but not negligible, and the criteria for AH have been based on only a few studies. The purpose of this study was to investigate the incidence, risk factors and possible mech...

    Authors: Chenglong Lu, Leyi Zhang, Jun Wang, Xiangyu Cao, Xin Jia, Xiaohui Ma, Ran Zhang, Lin Wang, Ying Yang, Fanchao Meng, Shengyuan Yu and Ruozhuo Liu
    Citation: The Journal of Headache and Pain 2022 23:20
  39. Migraine is a common neurovascular disorder that has a severe impact on the individual daily life. Atogepant (AGN-241689) is an orally ingested, small-molecule drugs belonging to calcitonin gene-related peptid...

    Authors: Xinyu Tao, Zeya Yan, Jiahao Meng, Wei Wang, Qiling Dai, Qiufeng Zhou, Zhifeng Wang and Zhong Wang
    Citation: The Journal of Headache and Pain 2022 23:19
  40. Whilst cranial autonomic symptoms (CAS) are typically associated with trigeminal autonomic cephalalgias (TAC’s), they have also been reported in migraine. Identification and understanding of these symptoms in ...

    Authors: Nazia Karsan, Karthik Nagaraj and Peter J. Goadsby
    Citation: The Journal of Headache and Pain 2022 23:18
  41. Migraine is a ubiquitous neurologic disease that afflicts people of all ages. Its molecular pathogenesis involves peptides that promote intracranial vasodilation and modulate nociceptive transmission upon rele...

    Authors: Astrid Wiggers, Håkan Ashina, Nouchine Hadjikhani, Abhay Sagare, Berislav V. Zlokovic, Martin Lauritzen and Messoud Ashina
    Citation: The Journal of Headache and Pain 2022 23:16
  42. As the relay centre for processing sensory information, the thalamus may involve in the abnormal sensory procedure caused by cortical spreading depression (CSD). However, few studies have focused on the transi...

    Authors: Xiaoxi Fu, Ming Chen, Jinling Lu and Pengcheng Li
    Citation: The Journal of Headache and Pain 2022 23:15
  43. Few prospective population-based studies have evaluated the bidirectional relationship between headache and affective disorder. The aim of this large-scale population-based follow-up study was to investigate w...

    Authors: Samita Giri, Erling Andreas Tronvik and Knut Hagen
    Citation: The Journal of Headache and Pain 2022 23:14
  44. After the initiation of the COVID-19 vaccination program in Thailand, thousands of patients have experienced unusual focal neurological symptoms. We report 8 patients with focal neurological symptoms after rec...

    Authors: Nijasri C. Suwanwela, Naruchorn Kijpaisalratana, Supatporn Tepmongkol, Wanakorn Rattanawong, Pongpat Vorasayan, Chutibhorn Charnnarong, Jarturon Tantivattana, Sirigunya Roongruang, Tatchaporn Ongphichetmetha, Poonnakarn Panjasriprakarn, Aurauma Chutinet, Wasan Akarathanawat and Jeffrey L. Saver
    Citation: The Journal of Headache and Pain 2022 23:13
  45. Noninvasive vagus nerve stimulation (nVNS) has recently emerged as a promising therapy for migraine. We previously demonstrated that vagus nerve stimulation inhibits cortical spreading depression (CSD), the el...

    Authors: Tzu-Ting Liu, Andreia Morais, Tsubasa Takizawa, Inge Mulder, Bruce J. Simon, Shih-Pin Chen, Shuu-Jiun Wang, Cenk Ayata and Jiin-Cherng Yen
    Citation: The Journal of Headache and Pain 2022 23:12
  46. Defining the relationship between a headache and stroke is essential. The current diagnostic criteria of the ICHD-3 for acute headache attributed to ischemic stroke are based primarily on the opinion of expert...

    Authors: Elena R. Lebedeva, Anton V. Ushenin, Natalia M. Gurary, Denis V. Gilev and Jes Olesen
    Citation: The Journal of Headache and Pain 2022 23:11
  47. The objective of this study was to describe patterns in monthly migraine days (MMD) and tablet utilization, and to estimate health-related quality of life (HRQoL) measures in patients treated as needed (PRN) w...

    Authors: Karissa Johnston, Linda Harris, Lauren Powell, Evan Popoff, Vladimir Coric, Gilbert L’Italien and Curtis P. Schreiber
    Citation: The Journal of Headache and Pain 2022 23:10